Abstract
House dust mites are one of the most important allergen sources worldwide and affect approximately 50% of asthmatic patients. Allergen-specific immunotherapy (AIT) is the only disease-modifying treatment for allergic diseases. However, clinical applications of allergen extract-based AIT were greatly restricted due to the potential adverse reactions. In order to improve the efficacy and reduce adverse effects, modified hypoallergens have been proposed for molecular forms of AIT. Therefore, in the present study, we converted the major house dust mite allergen Der f 34 into a B cell epitope-based hypoallergenic vaccine by the immunoinformatics and peptide-carrier fusion approaches. Initially, the physiochemical and structural properties of Der f 34 were analyzed. Accordingly, the linear and conformational B cell epitopes, as well as the helper T lymphocytes epitopes, were computed based on the properties of Der f 34. Three different fragments (residues 12–18, 83–89, and 98–116) of major allergen Der f 34 that containing candidate B cell epitope and that without T cell epitopes were linked at the N terminal and C terminal of the PreS carrier. The three-dimensional structure of the final vaccine was then predicted and the interaction with immune receptors (toll-like receptor-3) was evaluated by ligand-receptor docking. The immunogenic profiles and immune response of the final vaccine were in silico assessed after immunization, which represented the vaccine could induce an effective immune response. In addition, the codon sequences of the vaccine were cloned and expressed in E.coli, the vaccine was purified and exhibited a lower IgE-binding ability. Our results indicated that the Der f 34 hypoallergen could be a potential vaccine candidate for molecular forms of AIT in the house dust mite allergy.
Similar content being viewed by others
Data Availability
The programs/software/datasets used and/or analyzed during the present study are all available at the websites in the Methods section.
References
Asturias JA, Ibarrola I, Arilla MC, Vidal C, Ferrer A, Gamboa PM, Viñuela JE, Sanz ML, Andreu C, Martínez A (2009) Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clin Exp Allergy 39:1088–1098
Banerjee S, Weber M, Blatt K, Swoboda I, Focke-Tejkl M, Valent P, Valenta R, Vrtala S (2014) Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine. J Immunol 192:4867–4875
Calderón MA, Kleine-Tebbe J, Linneberg A, De Blay F, De Rojas DHF, Virchow JC, Demoly P (2015a) House dust mite respiratory allergy: an overview of current therapeutic strategies. J Allergy Clin Immunol Pract 3:843–855
Calderón MA, Linneberg A, Kleine-Tebbe J, De Blay F, De Rojas DHF, Virchow JC, Demoly P (2015b) Respiratory allergy caused by house dust mites: what do we really know? J Allergy Clin Immunol 136:38–48
Cao H, Liu Z (2020) Clinical significance of dust mite allergens. Mol Biol Rep 47:6239–6246
Chen KW, Blatt K, Thomas WR, Swoboda I, Valent P, Valenta R, Vrtala S (2012) Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. J Allergy Clin Immunol 130:435-443.e434
Colovos C, Yeates TO (1993) Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci 2:1511–1519
Curin M, Huang HJ, Garmatiuk T, Gutfreund S, Resch-Marat Y, Chen KW, Fauland K, Keller W, Zieglmayer P, Zieglmayer R, Lemell P, Horak F, Hemmer W, Focke-Tejkl M, Flicker S, Vrtala S, Valenta R (2021) IgE epitopes of the house dust mite allergen Der p 7 are mainly discontinuous and conformational. Front Immunol 12:687294
Dong R, Chu Z, Yu F, Zha Y (2020) Contriving multi-epitope subunit of vaccine for COVID-19: immunoinformatics approaches. Front Immunol 11:1784
Elramlawy KG, Fujimura T, Baba K, Kim JW, Kawamoto C, Isobe T, Abe T, Hodge-Hanson K, Downs DM, Refaat IH, Beshr Al-Azhary D, Aki T, Asaoku Y, Hayashi T, Katsutani T, Tsuboi S, Ono K, Kawamoto S (2016) Der f 34, a novel major house dust mite allergen belonging to a highly conserved Rid/YjgF/YER057c/UK114 family of imine deaminases. J Biol Chem 291:21607–21615
Gharbavi M, Danafar H, Amani J, Sharafi A (2021) Immuno-informatics analysis and expression of a novel multi-domain antigen as a vaccine candidate against glioblastoma. Int Immunopharmacol 91:107265
Heo L, Park H, Seok C (2013) GalaxyRefine: protein structure refinement driven by side-chain repacking. Nucleic Acids Res 41:W384-388
Jensen-Jarolim E, Roth-Walter F, Jordakieva G, Pali-Schöll I (2021) Allergens and adjuvants in allergen immunotherapy for immune activation, tolerance, and resilience. J Allergy Clin Immunol Pract 9:1780–1789
Jeong KY, Park JW, Hong CS (2012) House dust mite allergy in Korea: the most important inhalant allergen in current and future. Allergy Asthma Immunol Res 4:313–325
Jespersen MC, Peters B, Nielsen M, Marcatili P (2017) BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res 45:W24-w29
Kringelum JV, Lundegaard C, Lund O, Nielsen M (2012) Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol 8:e1002829
Laskowski RA, Macarthur MW, Moss DS, Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26:283–291
Laskowski RA, Swindells MB (2011) LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 51:2778–2786
Lüthy R, Bowie JU, Eisenberg D (1992) Assessment of protein models with three-dimensional profiles. Nature 356:83–85
Niederberger V, Valenta R (2006) Molecular approaches for new vaccines against allergy. Expert Rev Vaccines 5:103–110
Niespodziana K, Focke-Tejkl M, Linhart B, Civaj V, Blatt K, Valent P, Van Hage M, Grönlund H, Valenta R (2011) A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 127:1562–1570
Pali-Schöll I, Deboer DJ, Alessandri C, Seida AA, Mueller RS, Jensen-Jarolim E (2020) Formulations for allergen immunotherapy in human and veterinary patients: new candidates on the horizon. Front Immunol 11:1697
Paul S, Sidney J, Sette A, Peters B (2016) TepiTool: a pipeline for computational prediction of T cell epitope candidates. Curr Protoc Immunol 114:18–19
Pomés A (2010) Relevant B cell epitopes in allergic disease. Int Arch Allergy Immunol 152:1–11
Ponomarenko J, Bui HH, Li W, Fusseder N, Bourne PE, Sette A, Peters B (2008) ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinform 9:514
Rahman KHS, Chowdhury EU, Sachse K, Kaltenboeck B (2016) Inadequate reference datasets biased toward short non-epitopes confound B-cell epitope prediction. J Biol Chem 291:14585–14599
Rapin N, Lund O, Bernaschi M, Castiglione F (2010) Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system. PLoS ONE 5:e9862
Sanches RCO, Tiwari S, Ferreira LCG, Oliveira FM, Lopes MD, Passos MJF, Maia EHB, Taranto AG, Kato R, Azevedo VAC, Lopes DO (2021) Immunoinformatics design of multi-epitope peptide-based vaccine against Schistosoma mansoni using transmembrane proteins as a target. Front Immunol 12:621706
Thomas WR (2015) Hierarchy and molecular properties of house dust mite allergens. Allergol Int 64:304–311
Tulaeva I, Kratzer B, Campana R, Curin M, Van Hage M, Karsonova A, Riabova K, Karaulov A, Khaitov M, Pickl WF, Valenta R (2020) Preventive allergen-specific vaccination against allergy: mission possible? Front Immunol 11:1368
Valenta R, Campana R, Focke-Tejkl M, Niederberger V (2016) Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: lessons from the past and novel mechanisms of action for the future. J Allergy Clin Immunol 137:351–357
Valenta R, Campana R, Niederberger V (2017) Recombinant allergy vaccines based on allergen-derived B cell epitopes. Immunol Lett 189:19–26
Valenta R, Karaulov A, Niederberger V, Zhernov Y, Elisyutina O, Campana R, Focke-Tejkl M, Curin M, Namazova-Baranova L, Wang JY, Pawankar R, Khaitov M (2018) Allergen extracts for in vivo diagnosis and treatment of allergy: is there a future? J Allergy Clin Immunol Pract 6:1845-1855.e1842
Walgraffe D, Mattéotti C, El Bakkoury M, Garcia L, Marchand C, Bullens D, Vandenbranden M, Jacquet A (2009) A hypoallergenic variant of Der p 1 as a candidate for mite allergy vaccines. J Allergy Clin Immunol 123:1150–1156
Yang J, Zhang Y (2015) I-TASSER server: new development for protein structure and function predictions. Nucleic Acids Res 43:W174-181
Zieglmayer P, Focke-Tejkl M, Schmutz R, Lemell P, Zieglmayer R, Weber M, Kiss R, Blatt K, Valent P, Stolz F, Huber H, Neubauer A, Knoll A, Horak F, Henning R, Valenta R (2016) Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine 11:43–57
Funding
This work was partially supported by the National Natural Science Foundation of China (81960301); the Natural Science Foundation of Jiangxi Province (20202BABL206043); Science and Technology Planning Project of Jiangxi Health Commission (20204495); the Key Project of Gannan Medical University (ZD201908); the Key Research and Development Project of Ganzhou.
Author information
Authors and Affiliations
Contributions
XWG, CL and ZQX designed and supervised the study. PYY, YZ and LXT carried out the analysis and wrote the manuscript. PYY and ZQX revised and edited the manuscript. All of the authors approved the final version of this article.
Corresponding authors
Ethics declarations
Conflicts of interests
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Yu, PY., Zhu, Y., Tan, LX. et al. Immunoinformatics Construction of B Cell Epitope-Based Hypoallergenic Der f 34 Vaccine for Immunotherapy of House Dust Mite Allergy. Int J Pept Res Ther 28, 17 (2022). https://doi.org/10.1007/s10989-021-10337-2
Accepted:
Published:
DOI: https://doi.org/10.1007/s10989-021-10337-2